8TE Stock Overview
Engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cannabis Poland S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.12 |
| 52 Week High | zł0.18 |
| 52 Week Low | zł0.03 |
| Beta | 0.78 |
| 11 Month Change | 0% |
| 3 Month Change | -1.74% |
| 1 Year Change | 314.67% |
| 33 Year Change | -76.17% |
| 5 Year Change | n/a |
| Change since IPO | 22.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8TE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.1% |
| 1Y | 314.7% | -19.0% | 7.2% |
Return vs Industry: 8TE exceeded the German Pharmaceuticals industry which returned -30.8% over the past year.
Return vs Market: 8TE exceeded the German Market which returned 0.9% over the past year.
Price Volatility
| 8TE volatility | |
|---|---|
| 8TE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8TE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8TE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2 | Michal Szary | www.cp-sa.pl |
Cannabis Poland S.A. engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. The company sells CBD oils and herbs, inhalers, and vaporizers, as well as cosmetics. It sells its products through HempWish.pl and Vapem.eu online stores.
Cannabis Poland S.A. Fundamentals Summary
| 8TE fundamental statistics | |
|---|---|
| Market cap | €6.54m |
| Earnings (TTM) | -€284.26k |
| Revenue (TTM) | €15.21k |
430.1x
P/S Ratio-23.0x
P/E RatioIs 8TE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8TE income statement (TTM) | |
|---|---|
| Revenue | zł65.55k |
| Cost of Revenue | zł95.35k |
| Gross Profit | -zł29.80k |
| Other Expenses | zł1.20m |
| Earnings | -zł1.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.025 |
| Gross Margin | -45.46% |
| Net Profit Margin | -1,869.25% |
| Debt/Equity Ratio | 8.1% |
How did 8TE perform over the long term?
See historical performance and comparison